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ABSTRACT
The epithelial-to-mesenchymal transition (EMT) is a
complex transcriptional program induced by trans-
forming growth factor 1 (TGF-1). Histone lysine-
specific demethylase 1 (LSD1) has been recognized
as a key mediator of EMT in cancer cells, but the
precise mechanism that underlies the activation and
repression of EMT genes still remains elusive. Here,
we characterized the early events induced by TGF-
1 during EMT initiation and establishment. TGF-1
triggered, 30–90 min post-treatment, a nuclear ox-
idative wave throughout the genome, documented
by confocal microscopy and mass spectrometry,
mediated by LSD1. LSD1 was recruited with phos-
phorylated SMAD2/3 to the promoters of prototypic
genes activated and repressed by TGF-1. After
90 min, phospho-SMAD2/3 downregulation reduced
the complex and LSD1 was then recruited with the
newly synthesized SNAI1 and repressors, NCoR1
and HDAC3, to the promoters of TGF-1-repressed
genes such as the Wnt soluble inhibitor factor 1 gene
(WIF1), a change that induced a late oxidative burst.
However, TGF-1 early (90 min) repression of tran-
scription also required synchronous signaling by re-
active oxygen species and the stress-activated ki-
nase c-Jun N-terminal kinase. These data elucidate
the early events elicited by TGF-1 and the priming
role of DNA oxidation that marks TGF-1-induced
and -repressed genes involved in the EMT.
INTRODUCTION
The epithelial-to-mesenchymal transition (EMT) is the
product of a complex transcriptional program that induces
mesenchymal characteristics in polarized epithelial cells.
These features include reduced cell–cell contacts, enhanced
migratory and invasive capacity, and resistance to apop-
tosis (1). EMT occurs during tumor progression to gener-
ate metastatic cells that are endowed with a more motile
and invasive phenotype (2). Several transcription factors
are implicated in EMT control; particularly, the repressor
SNAI1, a member of the zinc finger transcription factor
family, is induced by transforming growth factor 1 (TGF-
1) to initiate the EMT transcription program (3). EMT
also critically depends on reactive oxygen species (ROS),
which support tumor growth by stimulating multiple path-
ways (4–6). Additionally, high oxidative stress levels in the
tumor microenvironment, due to both hypoxia and stro-
mal inflammatory cell recruitment, can promote myofibrob-
*To whom correspondence should be addressed. Tel: +39 0817463614; Email: antoniopezone@gmail.com; antonio.pezone@unina.it
Correspondence may also be addressed to Paola Chiarugi. Tel: +39 0552751247; Email: paola.chiarugi@unifi.it
Correspondence may also be addressed to Enrico Vittorio Avvedimento. Tel: +39 0817463251; Email: avvedim@unina.it
†The authors wish it to be known that, in their opinion, the first three authors should be regarded as Joint First Authors.
C© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work




















IA user on 28 July 2020
2 Nucleic Acids Research, 2020
last differentiation into activated cancer-associated fibrob-
lasts (CAFs) (7–9). CAFs, in turn, exploit the oxidative
stress to produce cytokines and proteases that can elicit
EMT in cancer cells (10). Moreover, CAFs induce EMT in
prostate carcinoma cells through a redox-dependent mech-
anism that involves nuclear factor B (NF-B), NADPH
oxidase (NOX), cyclooxygenase and hypoxia-inducible fac-
tor 1 (HIF-1) to sustain tumor progression and metastatic
dissemination (11).
ROS and DNA oxidation are also linked to transcrip-
tion. Demethylation of histone H3 by histone lysine-specific
demethylase (LSD1) is stimulated by estrogen and retinoic
acid. ROS produced by LSD1 induce oxidation of deoxy-
G (oxo-dG), a process that is instrumental for the assembly
of a productive transcriptional initiation complex and the
formation of transcriptional loops (12,13). In this scenario,
the aim of our work was to explore whether a similar mech-
anism, dependent on nuclear ROS production, could be the
driving force behind the transcriptional program leading to
EMT in mammary epithelial cells induced by TGF-1 dur-
ing the initiation of EMT.
We report here that TGF-1 triggers an early (30 min)
oxidative wave in the nucleus, mediated by LSD1, recruited
and targeted by phosphorylated SMAD2/3 to the promot-
ers of activated and repressed TGF-1/EMT genes. At 90
min, there was a second oxidative wave, detected by the ac-
cumulation of oxo-dG glycosylase, OGG1, only at TGF--
repressed genes. At these promoters, a repressive complex
was formed by LSD1 and HDAC3–NCoR1 with the newly
synthesized repressor SNAI1. Early (30–90 min) DNA oxi-
dation mediated by LSD1 was necessary for both activation
and repression of transcription by TGF-1. Transcriptional
repression by TGF-1 required an additional signal gener-




PVDF membrane was obtained from Millipore (Bed-
ford, MA, USA); anti-E-cadherin, anti-N-cadherin,
anti-SET7/9, anti-OGG1/2, anti-HDAC3, LSD1 shRNA
plasmid and JMJD2a shRNA plasmid were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
anti-FLAG and anti-smooth muscle actin antibody
and Phalloidin-TRITC were obtained from Sigma-
Aldrich (St Louis, MO, USA); DCFDA and Alexa
488 secondary antibody were obtained from Molecular
Probes; anti-H3K4me2, anti-H3K4me3, anti-H3K9me2,
anti-H3K9me3, anti-H3, anti-LSD1, anti-JMJD2A,
anti-SUV39H1, anti-NCoR1, anti-APE1, anti--actin,
anti--tubulin antibodies, anti-IgG mouse and anti-IgG
rabbit were obtained from Abcam (Cambridge, UK); anti-
pSMAD2/3 (Ser 423/425) and anti-SMAD2/3 antibodies
were obtained from Cell Signaling Technology (Danvers,
MA, USA); anti-8-oxo-dG antibodies were obtained from
Trevigen Inc. (Gaithersburg, MD, USA); and the OxyDNA
assay was obtained from Calbiochem (San Diego, CA,
USA).
Cell cultures, transfections and drug pretreatments
MCF10A cells were obtained from the American Type
Culture Collection. MCF10A cells were cultured in
DMEM/Ham’s F12 supplemented with 5% horse serum,
0.5 g/ml hydrocortisone, 100 ng/ml cholera toxin, 20
ng/ml EGF and 10 g/ml insulin. Before TGF-1 stim-
ulation, the cells were starved in serum-free medium con-
taining DMEM/Ham’s F12 supplemented with 0.5 g/ml
hydrocortisone, 100 ng/ml cholera toxin, 20 ng/ml EGF
and 10 g/ml insulin for 24 h. TGF-1 (10 ng/ml) was
added to the cultures at different times (30–60–90 min or
12–24 h). Where necessary, MCF10A cells were pretreated
with N-acetylcysteine (NAC, 5 mM), diphenyleneiodonium
(DPI, 10 M), tranylcypromine (TCP, 0.5–1 mM), JIB04
(23 mM), SP600125 (10 M), SB431542 (10 M), apocynin
(50 M) and rotenone (5 M). Several LSD1 inhibitors,
SP2509 and CBB1007 (noncatalytic, reversible inhibitors)
and OG-L002 and GSK (catalytic MAO inhibitors) (see
selleckchem.com/lsd1.html), were tested on MCF10A cells.
All of them but TCP reduced the growth at 24–36 h of
MCF10A cells at concentrations used (A. Pezone, unpub-
lished data) (14,15).
LSD1–JMJD2A silencing
MCF10A cells were transfected with LSD1 or JMJD2A
shRNA/hairpin vectors using Lipofectamine 3000 (Invit-
rogen, Waltham, MA, USA) according to manufacturer’s
instructions or by electroporation. Four single or pooled
shRNA/hairpin vectors (Santa Cruz Biotech, LSD1sh sc-
60970 and JMJD2A sc-62515) targeting different LSD1 or
JMJD2A segments were transfected in MCF10A cells. Af-
ter 24 h, the cells were exposed to TGF-1 and the levels
of JMJD2A, LSD1, -actin, GADPH, -tubulin mRNAs
and 18S RNA were measured by qPCR or immunoblot
with specific antibodies (except 18S RNA). In some experi-
ments, the wild-type human LSD1 expression vector with-
out the 3′-UTR was included in the transfection to con-
trol off-target effects in experiments with single or pooled
shRNA/hairpin vectors (Supplementary Figure S2).
Immunoprecipitation and immunoblot analysis
A total of 1 × 106 cells were lysed for 20 min on ice in
500 l of complete RIPA lysis buffer (50 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 2 mM EGTA,
1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl
fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin). Lysates
were clarified by centrifugation and immunoprecipitated for
4 h at 4◦C with 1–2 g of the specific antibodies. Immune
complexes were collected on Protein A/G PLUS agarose,
separated by SDS-PAGE and transferred onto nitrocellu-
lose. Immunoblots were incubated in 3% milk, 10 mM Tris–
HCl, pH 7.5, 1 mM NaCl and 0.1% Tween 20 for 1 h at room
temperature, probed first with specific antibodies and then
with secondary antibodies.
Real-time PCR
Total RNA from MCF10A was extracted using TRIzol
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h at 50◦C, and the reaction was heat inactivated for 15 min
at 70◦C. The primers used are shown in Supplementary Ta-
ble S1. Data were normalized to 18S RNA. Results (mean
± SD) are the mean of three different experiments in tripli-
cate.
Immunocytochemistry
After washing with phosphate-buffered saline (PBS), cells
were fixed with 3.7% formaldehyde solution in PBS for
20 min at 4◦C. After extensive washing in PBS, cells
were permeabilized with 0.1% Triton X-100 in PBS and
then stained with anti-E-cadherin antibody overnight and
with 50 g/ml fluorescent phalloidin conjugate, phalloidin-
TRITC, in PBS for 1 h at room temperature and then with
anti-rabbit Alexa 488 secondary antibodies. After washing
with PBS, the cover slides were mounted with glycerol and
then observed under a confocal fluorescence microscope
(Leica Microsystems).
8-Oxo-G assay
Immunocytochemistry was performed according to the
manufacturer’s instructions (Trevigen Inc.). The anti-8-oxo-
dG antibodies (mouse monoclonal 15A3) were validated by
confocal microscopy (16) and chromatin immunoprecipita-
tion (ChIP) (17). The signal was resistant to RNase A and
sensitive to DNase I and NAC. Briefly, cells were fixed for
15 min with MeOH at −20◦C followed by 15 min at −20◦C
with acetone. Fixed cells were treated with 0.05 N HCl for 5
min on ice and incubated with 250 l of 100 g/ml RNase
A in 150 mM NaCl and 15 mM sodium citrate for 1 h at
37◦C. After sequentially washing in 1× PBS and 35%, 50%
and 75% ethanol (EtOH), DNA was denatured in situ with
250 l of 0.15 N NaOH in 70% EtOH. A 0.2 g/ml (250
l) TO-PRO-3 Iodide (Thermo Fisher Scientific) in 1× PBS
was used to stain DNA for 10 min. After several washing
with 70% EtOH containing 4% v/v formaldehyde, 50% and
35% EtOH, and 1× PBS, the cells were incubated in 250 l
of 5 g/ml proteinase K in 20 mM Tris and 1 mM EDTA,
pH 7.5 (TE), for 10 min at 37◦C. Nonspecific binding was
prevented by incubation with 5% normal goat serum in 1×
PBS for 1 h at room temperature. Then, fixed cells were in-
cubated with 250 l anti-8-hydroxyguanine antibody at a
concentration of 1:250 diluted in 1× PBS containing 1%
bovine serum albumin (BSA) and 0.01% Tween 20 at 4◦C
overnight in a humidified chamber. After several washing
with 1× PBS containing 0.05% Tween 20, fixed cells were
incubated cells in 250 l of fluorescent secondary antibody,
goat anti-mouse IgG (Alexa Fluor 488), at 5 g/ml in 1×
PBS containing 1% BSA for 1 h in the dark at room tem-
perature. After extensive washing, cells were mounted with
glycerol and observed by a laser scanning confocal micro-
scope.
Colocalization of 8-oxo-G signals in confocal microscopy
Colocalization of confocal images was performed with two
specific plugins of ImageJ: (i) Colocalisation (http://www.
sussex.ac.uk/gdsc/intranet/pdfs/Colocalisation.pdf) and (ii)
Coloc 2 (https://imagej.net/Coloc 2). Briefly, two points
colocalized if their ratio of intensity was higher than the set-
ting value (50 was used as default setting value). To normal-
ize to the number of the cells in each field, the values were
expressed as the percentage of the area of the cell nuclei in
each individual photo. The area of non-colocalized green
spots was measured as percentage of the area of the nuclei.
For each sample, Pearson’s correlation and Manders’ split
coefficient were calculated.
Intracellular ROS determination
Production of intracellular H2O2 was assayed as previously
described (18). At 3 min before the end of the incubation
time, DCFDA was added to a final concentration of 5 M.
Cells were lysed in 1 ml of RIPA buffer and analyzed im-
mediately by fluorescence analysis using a Perkin Elmer
Fluorescence Spectrophotometer 650-10S equipped with a
xenon power supply (excitation 488 nm, emission 510 nm).
2D ultra-performance liquid chromatography–tandem mass
spectrometry
The 2D ultra-performance liquid chromatography–tandem
mass spectrometry (UPLC–MS/MS) analysis was per-
formed following our recently developed method (19).
Briefly, DNA hydrolysates were spiked with a mixture of in-
ternal standards in a volumetric ratio of 4:1, to concentra-
tion of 50 fmol/l of [D3]-5-hydroxymethyl-dC (5-hmdC),
[13C10, 15N2]-5-formyl-2′-deoxycytidine, [13C10, 15N2]-5-
carboxyl-2′-deoxycytidine, [13C10, 15N2]-5-hydroxymethyl-
2′-deoxyuridine (5-hmdU) and [15N5]-8-oxo-dG. Chro-
matographic separation was performed with a Waters Ac-
quity 2D UPLC system with a photodiode array detector,
for the first-dimension chromatography, used for the quan-
tification of unmodified deoxynucleosides and 5-methyl-
2′-deoxycytidine, and a Xevo TQ-S tandem quadrupole
mass spectrometer for the second-dimension chromatogra-
phy. An at-column dilution technique was used between
first and second dimensions for improving retention at
the trap/transfer column. The columns used were a Phe-
nomenex Kinetex C-18 column (150 mm × 2.1 mm, 1.7
m) at the first dimension, a Waters X-select C18 CSH
(30 mm × 2.1 mm, 1.7 m) at the second dimension and
Waters X-select C18 CSH (30 mm × 2.1 mm, 1,7 m) as
the trap/transfer column. The chromatographic system op-
erated in the heart-cutting mode, indicating that selected
parts of effluent from the first dimension were directed to
the trap/transfer column via six-port valve switching, which
served as ‘injector’ for the second-dimension chromatogra-
phy system. The flow rate at the first dimension was 0.25
ml/min and the injection volume was 0.5–2 l. The separa-
tion was performed with a gradient elution for 10 min using
a mobile phase of 0.1% acetate (A) and acetonitrile (B) (1–
5% B for 5 min, column washing with 30% acetonitrile and
re-equilibration with 99% A for 3.6 min). The flow rate at
the second dimension was 0.35 ml/min. The separation was
performed with a gradient elution for 10 min using a mobile
phase of 0.01% acetate (A) and methanol (B) (4–50% B for 4
min, isocratic flow of 50% B for 1.5 min and re-equilibration
with 96% A up to next injection). All samples were analyzed
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was used for further calculation. Mass spectrometric detec-
tion was performed using the Waters Xevo TQ-S tandem
quadrupole mass spectrometer, equipped with an electro-
spray ionization source. Collision-induced dissociation was
obtained using argon 6.0 at 3 × 10−6 bar pressure as the
collision gas. Transition patterns for all the analyzed com-
pounds as well as specific detector settings were determined
using the MassLynx 4.1 IntelliStart feature.
Chromatin immunoprecipitation
MCF10A cells were grown to 95% confluence in
DMEM/Ham’s F12. Following the addition of 10
ng/ml TGF-1 for 30, 60 and 90 min, cells were washed
twice with PBS and cross-linked with 1% formaldehyde
at room temperature for 10 min. Cells then were washed
with ice-cold PBS containing protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 g/ml aprotinin and 1
g/ml pepstatin A). Cells were then resuspended in 0.2 ml
of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl,
pH 8.1, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml
aprotinin and 1 g/ml pepstatin A), sonicated for 17
cycles (12 s followed by 28 s of stop) and centrifuged for
10 min at 10 000 × g at 4◦C. Supernatants were collected
and diluted in buffer containing 1% Triton X-100, 2 mM
EDTA, 150 mM NaCl and 20 mM Tris–HCl, pH 8.1.
Immunoprecipitation was performed overnight at 4◦C with
2 g of specific antibodies with 14 l Protein G Dynabeads
(Invitrogen, Waltham, MA, USA). After immunoprecip-
itation, precipitates were washed sequentially for 10 min
each in high-salt solution (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris–HCl, pH 8.1, 150 mM NaCl),
low-salt solution (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris–HCl, pH 8.1, 500 mM NaCl) and
LiCl solution (0.25 M LiCl, 1% NP-40, 1% deoxycholate,
1 mM EDTA, 10 mM Tris–HCl, pH 8.1). Precipitates
were then washed three times with TE buffer and extracted
two times with 1% SDS and 0.1 M NaHCO3. Eluates
were pooled and heated at 65◦C overnight to reverse the
formaldehyde cross-linking. DNA fragments were purified
with a QIAquick Spin Kit (Qiagen, Valencia, CA, USA).
The primers used are shown in Supplementary Table S1.
Statistical analysis
The data we present derive from at least three biological
and three technical replicates. Multivariate analysis of vari-
ance (MANOVA) or repeated measures analysis of variance
(ANOVA) was used to determine differences in multiple de-
pendent variables over time or between treatments. Each
figure is associated with specific statistical figures indicated
as Figure x-Stat.y. Statistical analysis of the data was per-
formed by Student’s t-test. P-values of ≤0.05 were consid-
ered statistically significant.
RESULTS
TGF-1-induced ROS were generated by multiple sources
and were all essential for the EMT program
TGF-1 evokes a time-dependent increase of ROS mea-
sured as DCF fluorescence that peaks at 30–45 min af-
ter treatment and thereafter declines, although remain-
ing significantly elevated above control even at 120 min
post-treatment (Figure 1A and Supplementary Figure 1-
Stat.1). As expected, ROS accumulation was sensitive to
antioxidant treatments, such as NAC and pegylated cata-
lase (Figure 1B and Supplementary Figure 1-Stat.1). TGF-
1-induced ROS were essential to initiate EMT, as revealed
by changes in the levels of N-cadherin, -SMA and E-
cadherin in cells exposed to TGF-1 and/or NAC (Figure
1C). Confocal microscopic analysis of E-cadherin distribu-
tion showed that ROS scavenging by NAC inhibited TGF-
1-induced EMT. Indeed, TGF-1-treated cells were more
dispersed, exhibited an elongated spindle-shaped morphol-
ogy and displayed well-organized actin stress fibers and re-
duced E-cadherin levels (Figure 1D and E). NAC treat-
ment inhibited the appearance of these features, data that
confirm, in MCF10 cells, EMT induction by TGF-1 was
strictly redox dependent (Figure 1E) (20,21). ROS induced
by TGF-1 are essentially produced by NADPH oxidase(s),
specifically NOX4 (22,23). NOX4 is the major NADPH ox-
idase in MCF10 cells and is induced by TGF-1 (24–26). A
fraction of NOX4 is localized in the mitochondria (27) and
is inhibited as the other NOX enzymes by DPI (28).
Loss of cell junctions, due to the switching of cadherin
and gene expression reprogramming during EMT establish-
ment, is under tight transcriptional control, which can be
regulated by ROS induced by TGF-1. In this context, the
induction of the repressor SNAI1 by TGF-1 is an essen-
tial and early step to initiate the EMT program (29). To
document the link between ROS and early transcriptional
changes induced by TGF-1, we measured the RNA lev-
els of two sets of prototypic genes that are activated or re-
pressed by TGF- 1 in the presence or absence of NAC and
DPI (28). These genes were selected from Affymetrix and
Illumina microarray platforms on the basis of their strong
correlation with other probes involved in EMT in breast
and lung cancer cells (30).
Very early upon TGF-1 exposure (30–90 min), NAC,
but not DPI, inhibited SNAI1 gene expression, data that
suggest the ROS required for SNAI1 induction were not
generated by NADPH oxidase (Figure 1F and Supple-
mentary Figure 1-Stat.2–4). The expression of other TGF-
1-induced genes, such as CDH2 (N-cadherin), VIM (vi-
mentin) and PAI (serpin1), at 90 min was also resistant
to DPI and inhibited by NAC (Figure 1F and Supple-
mentary Figure 1-Stat.2–4). Conversely, the expression of
WIF1, MYC (c-Myc oncogene), CDH1 (E-cadherin) and
DSP (desmoplakin 1) genes was repressed by TGF-1 and
reactivated by both NAC and DPI (Figure 1G and Supple-
mentary Figure 1-Stat.5–7). Although DPI is not a specific
NOX inhibitor, the different sensitivity of TGF--induced
and -repressed genes to DPI (not NAC) suggests that ROS
induced by TGF-1 derive from different sources. To link
early and late events induced by TGF-1, we measured the
induction of SNAI1 and NOX4 in cells exposed for 24 h to
TGF-1 in the presence or absence of DPI. Supplementary
Figure S1B shows that at 24 h the induction of SNAI and
NOX4 by TGF-1 was inhibited by DPI, suggesting that at
24 h both induced and repressed genes were dependent on
the same source of ROS induced by TGF-1, which most





















IA user on 28 July 2020
Nucleic Acids Research, 2020 5
Figure 1. TGF-1-induced ROS are essential for EMT establishment. (A, B) ROS induced by TGF-1. (A) Cells were serum starved for 24 h before
stimulation with 10 ng/ml TGF-1 for the indicated times. H2O2 production was evaluated as described in the ‘Materials and Methods’ section. (B) Cells
were pretreated with 5 mM NAC or 1 g/ml catalase for 15 min before stimulation with 10 ng/ml TGF-1 for 30 min. The data presented are the mean of
at least three experiments in duplicate (n = 6). Comparison between three or more samples was performed with one-way ANOVA test; comparison between
each pairs was performed with Student’s t-test: *P < 0.01 versus untreated control; **P < 0.01 versus TGF-1 alone (see Supplementary Figure 1-Stat.1).
(C) E–N cadherin switch and -SMA levels induced by TGF-1. Cells were pretreated with 5 mM NAC for 15 min and then stimulated with 10 ng/ml
TGF-1. After 72 h, the cells were lysed and subjected to immunoblot analysis for E-cadherin, N-cadherin, -SMA and -actin. (D) Photographs of cells
exposed to 10 ng/ml TGF-1 for 72 h were taken with a phase/contrast microscope. (E) Representative images of cells exposed to 10 ng/ml TGF-1 for
72 h, fixed and examined by immunofluorescence microscopy of phalloidin in red and E-cadherin in green in the presence of NAC. (F, G) MCF10A cells
were pretreated with 5 mM NAC or 5 M DPI for 15 min before stimulation with 10 ng/ml TGF-1 for 90 min. Total RNA was extracted and analyzed by
qRT-PCR with primers corresponding to SNAI1, CDH2, VIM and PAI mRNA (F) and WIF1, cMYC, CDH1 and DSP genes (Supplementary Table S1)
(G). The data shown are the mean of at least three experiments performed three times (n ≥ 9). A separate MANOVA was used to examine the association
between the mRNA levels after TGF-1 and NAC/DPI treatment; the interaction was significant (see Supplementary Figure 1-Stat.2 for panel F and
Supplementary Figure 1-Stat.5 for panel G). Univariate testing found the effect to be significant for both NAC and DPI (see Supplementary Figure
1-Stat.3 for panel F and Supplementary Figure 1-Stat.6 for panel G). *P < 0.01 versus CTRL + TGF-1; ◦P < 0.01 versus basal CTRL (without TGF-
1). Pairwise comparison to evaluate the response to TGF-1 was performed with Student’s t-test (see Supplementary Figure 1-Stat.4 for panel F and
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Nuclear G oxidation by LSD1 promoted TGF-1 activation
and repression of transcription
To identify the early (30–90 min) ROS sources induced by
TGF-1 that prime the cells to initiate EMT, we focused
our attention on the nucleus. Rather than measuring nu-
clear ROS, which are extremely unstable and diffuse across
membranes, we determined the accumulation of the ma-
jor DNA oxidation product, 8-oxo-dG, by confocal mi-
croscopy using specific antibodies against 8-oxo-dG. Figure
2A shows significant accumulation of nuclear 8-oxo-dG af-
ter 30-min TGF-1 treatment, in strict concomitance with
the increased ROS levels (Figure 1A) and EMT engagement
(Figure 1C). NAC inhibited the oxo-dG levels induced by
TGF-. DPI treatment reduced TGF-1-induced nuclear
8-oxo-dG and increased the 8-oxo-dG signal, mainly in the
perinuclear area (Figure 2A, and Supplementary Figures
S1B and S1-Stat.2–3).
8-Oxo-dG has been implicated in transcriptional regu-
lation by a variety of signals, including nuclear hormones
such as estrogens (12), retinoic acid (13) and c-Myc (31)
or hypoxia (32). Histone demethylation is a redox reaction,
and under myriad circumstances it induces deoxy-G oxi-
dation (12,13). The enzymes involved in histone demethy-
lation are mono- or dioxygenases; LSD1 or KDM1 is a
monooxygenase that generates hydrogen peroxide during
the demethylation reaction (33). Since LSD1 has been asso-
ciated with EMT engagement and SNAI1-mediated repres-
sion of epithelial markers (34), we investigated whether the
nuclear oxidation wave induced by TGF-1 was generated
by LSD1. To this end, we silenced LSD1 in MCF10A cells
by shRNA (Supplementary Figure S1D) interference and
measured 8-oxo-dG upon TGF-1 stimulation. LSD1 si-
lencing was as effective as NAC (compare Figure 2A and B)
at inhibiting TGF-1-induced deoxy-G oxidation (Figure
2B, and Supplementary Figures S1C and D and S1-Stat.4–
5). Additionally, treatment of the cells with a monoamine
oxidase inhibitor, namely TCP (15,35), abolished the nu-
clear 8-oxo-dG signal (Figure 2A and Supplementary Fig-
ure S1B). These data showed that LSD1 is the source of
nuclear ROS and the cause of G oxidation. As a logical
extension of the previous experiment, we analyzed EMT
engagement in MCF10A cells upon LSD1 depletion. Con-
focal analysis of cortical E-cadherin and actin stress fibers
confirmed that LSD1 silencing inhibited EMT induced by
TGF-1 (Figure 2C).
The data reported above show that the nuclear TGF-1-
induced ROS were produced by LSD1 (Figure 2B) and that
LSD1 depletion inhibited the EMT/TGF-1 response (Fig-
ure 2C). To document the impact of LSD1 on the expres-
sion of the genes involved in EMT, we measured SNAI1
and other TGF-1-induced or -repressed mRNA levels in
LSD1-depleted cells. LSD1 knockdown abolished SNAI1
induction as well as the induction of CDH2, VIM and
PAI by TGF-1 (Figure 2D and Supplementary Figure 2-
Stat.1–2). Moreover, LSD1 silencing reversed TGF-1 re-
pression of genes such as WIF1, cMYC, CDH1 and DSP
(Figure 2E and Supplementary Figure 2-Stat.3–4). Further-
more, treatment of the cells with TCP, the monoamine ox-
idase inhibitor (15,35), inhibited the TGF-1-mediated in-
duction of SNAI1, CDH2, VIM and PAI and prevented the
TGF-1-mediated repression of WIF1, MYC, CDH1 and
DSP, replicating LSD1 depletion effects (Figure 2F, Sup-
plementary Figure 2-Stat.5–6, Figure 2G and Supplemen-
tary Figure 2-Stat.7–8). The effects of LSD1 shRNAs on
SNAI1 and WIF1 induction or inhibition of transcription
were prevented by expressing exogenous LSD1 (Supple-
mentary Figure S2).
TGF-1 induced a genome-wide temporal oxidation wave
that modified the DNA
Confocal microscopy revealed that TGF-1 treatment in-
duced 8-oxo-dG nuclear signal; it was eliminated by LSD1
depletion (Figure 2B). To confirm this finding with a differ-
ent technique, we subjected the DNA of TGF-1-exposed
cells to MS analysis to identify and quantify the modified
DNA bases (see the ‘Materials and Methods’ section). Fig-
ure 3A shows that 8-oxo-dG levels were induced by TGF-1
after 60–90 min (Figure 3A and Supplementary Figure 3-
Stat.1A). Induction of 8-oxo-dG by TGF-1 was prevented
by DPI or LSD1 depletion (Figure 3A and Supplementary
Figure 3-Stat.3A and 4A). Apocynin, a nonspecific antioxi-
dant, that inhibits peroxides (36) did not modify the 8-oxo-
dG levels induced by TGF-1 (Figure 3A, right panel, and
Supplementary Figure 3-Stat.3).
Analysis of the other modified DNA bases revealed that
the TGF-1 effects on DNA also involve deoxy-C metabo-
lites: 5-hmdC and 5-methyl-dC (Figure 3B and C, and Sup-
plementary Figure 3-Stat.1-2B and C). Furthermore, 5-
hmdU or deoxy-U levels were reduced by DPI, data that
suggest oxidation by NOX enzymes favors C and T deam-
ination (Figure 3D and E, and Supplementary Figure 3-
Stat.1–2D and E and 3-Stat.3).
To our knowledge, these data provide the first demonstra-
tion that TGF-1 induces a genome-wide oxidation wave
that modifies DNA to initiate the EMT transcriptional pro-
gram.
Common and differential chromatin changes induced by
TGF-1 at repressed and activated promoters
The above data demonstrate that LSD1 is required for
DNA oxidation and for both the activation and repres-
sion of TGF-1-induced transcription, but they do not clar-
ify the mechanism. TGF-1-activated receptors I and II
induce a series of events that culminate in the phospho-
rylation and nuclear accumulation of the phosphorylated
SMAD2/3 complex (37). We analyzed by ChIP the earli-
est chromatin changes (30–60 min) at the promoter sites
of the two prototypic genes induced (SNAI1) or repressed
(WIF1) by TGF-1. The analyzed genomic regions contain
sequences recognized by the complex SMAD2/3 (37,38) (A.
Pezone, unpublished data). Upon TGF-1 challenge, phos-
phorylated SMAD2/3 (pSMAD2/3) complex was recruited
to the SNAI1 and WIF1 promoters and steadily accumu-
lated at 30 min and disappeared by 90 min (Figure 4A and
B). LSD1 was also recruited after 30 min at both promoters,
but at 90 min, compared to 0- or 60-min treatment, LSD1
accumulated at WIF1 promoter (Figure 4A and B, and Sup-
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Figure 2. Nuclear G oxidation induced by TGF-1 through the histone demethylase, LSD1. (A) Immunofluorescence detection of 8-oxo-dG by fluorescein-
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LSD1 and pSMAD2/3 suggests that these proteins form a
transient complex at both promoters. The association be-
tween LSD1 and pSMAD2/3 was shown by immunoprecip-
itation with antibodies to LSD1 and immunoblot with anti-
pSMAD2/3 (Figure 4D) or immunoprecipitation with anti-
bodies to an exogenous FLAG–LSD1 and western blot with
anti-pSMAD2/3 antibodies in extracts derived from trans-
fected cells (Figure 4E). The association was also shown by
ChIP and re-ChIP experiments of SNAI1 and WIF1 pro-
moters with antibodies against LSD1 on pSMAD2/3 (Fig-
ure 4G and H, and Supplementary Figure 4-Stat.2). Both
assays (immunoprecipitation and ChIP) revealed that non-
phosphorylated SMAD2/3 did not bind LSD1. However,
the absence of signal with the antibody to total SMAD2/3
suggests that only a fraction of SMAD2/3 binds LSD1
(Figure 4F). The complex that contained pSMAD2/3 was
transient (30 min) and rapidly disappeared at the SNAI1
promoter between 60 and 90 min after TGF-1 treatment
(Figure 4A). LSD1 reappeared at the WIF1 promoter 90
min after TGF-1 treatment, without pSMAD2/3 (Figure
4B and Supplementary Figure 4-Stat.1C and D). The no-
tion that pSMAD2/3 is recruited to promoters repressed by
TGF-1 is not novel, although it has not been connected to
a specific mechanism (36). Phosphorylated SMAD2/3 work
as pioneer factors that transiently bind DNA sites present
in TGF-1-induced or -repressed promoters in different cell
types (38,39). Depending on the concomitant presence of
other signals, such as ROS and stress-kinase-induced re-
pressors (40,41), some genes are repressed while others are
activated. For example, the repressor SNAI1 was induced
at 30 min after TGF-1 challenge and recruited at 90 min
to the WIF1 promoter, where it formed a complex with
LSD1 and silenced the expression of the gene (Supplemen-
tary Figures S3 and S3-Stat.1A–C). With the same timing,
the co-repressors NCoR1 and HDAC3 accumulated at the
WIF promoter (Supplementary Figures S4A and B, and S4-
Stat.1).
Collectively, these data demonstrate that the
pSMAD2/3–LSD1 complex very early upon TGF-1
challenge targeted the chromatin of TGF-1-activated and
-repressed promoters (Figure 4A and B). Ninety minutes
after TGF-1 challenge, SNAI1 and LSD1 accumulated
preferentially at the repressed promoters (Figure 4A and
B). Since nuclear G oxidation was the earliest modifica-
tion we observed upon TGF-1 challenge, we measured
recruitment of OGG1 and the apurinic/apyrimidinic
endonuclease 1 (APE1) to the SNAI1 and WIF1 promoters.
OGG1 recognizes 8-oxo-dG and APE1 targets, excises
and repairs the abasic site generated by OGG1 (42). Since
LSD1 demethylates H3K4 and K9m2, we also determined
at the same sites the H3K4-K9 methylation status and
the recruitment of H3K9 and H3K4 methyltransferases,
SUV39 and SET7/9 (43,44).
In summary, OGG1 accumulated at 30 min at the
SNAI1 promoter (Figure 5A and Supplementary Figure 5-
Stat.1A–C) and at 30 and 90 min at the WIF1 promoter
(Figure 5B and Supplementary Figures 5-Stat.1D–F and
S3B), a pattern that mirrored the timing of LSD1 recruit-
ment at the same sites (Figure 4A and B). The presence
of APE1 at both promoters 90 min after TGF-1 treat-
ment suggests a prolonged repair step, such as long-patch
base excision repair, following dG oxidation (45,46) at both
promoters. At WIF1 promoter, the second oxidation peak
is marked by OGG1 and overlaps with the rise of 8-oxo-
dG levels at 90 min detected by MS (Figure 3A). With the
same timing, NCoR1 and HDAC3 accumulate at the WIF1
promoter (Supplementary Figure S4B). Since the TGF-1-
induced dG oxidation is dependent on LSD1 (Figures 2 and
3) and LSD1 demethylates H3K9 and H3K4m2 (12,13), we
have asked whether LSD1 contributes to the H3K9 and
H3K4 methylation status of SNAI1 and WIF1 chromatin
during the early response to TGF-1. Histone H3 methyla-
tion changes induced by TGF-1 at the SNAI1 and WIF1
promoters are produced by the recruitment of demethy-
lases and methyltransferases (43,44). Following TGF-1
stimulation, both K9 and K4 methyltransferases, SUV39
and SET7/9, respectively, were recruited to the SNAI1 and
WIF1 promoters with similar kinetics (Supplementary Fig-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
were stained with TO-PRO-3 Iodide in red while 8-oxo-dG foci were stained in green, as described in the ‘Materials and Methods’ section. Fluores-
cence quantization and statistical analysis are shown in Supplementary Figures S1C and S1-Stat3–6. (B) Immunofluorescence detection of 8-oxo-dG by
fluorescein-tagged anti-8-oxo-dG antibody in cells transfected with scrambled short hairpin (shCTRL) and shLSD1 RNAs for 24 h before stimulation with
10 ng/ml TGF-1 for 30 min. Nuclei were stained with TO-PRO-3 Iodide in red while 8-oxo-dG foci were stained in green. Colocalization was measured
using ImageJ (Coloc 2 plugin) as described in the ‘Materials and Methods’ section. Fluorescence quantization and statistical analysis are shown in Sup-
plementary Figures S1D and S1-Stat3–6. (C) Immunofluorescence microscopy of phalloidin in red and E-cadherin in green in control or LSD1-depleted
cells exposed to 10 ng/ml TGF-1 for 72 h. (D–G) mRNA levels of genes regulated by TGF-1 in cells treated with shLSD1 or with TCP. Results are
the mean of at least three experiments performed three times (n = 9). MANOVA was used to examine the association between the mRNA levels after
TGF-1 and LSD1 depletion; the interaction was significant (see Supplementary Figure 2-Stat.2 for panel D and Supplementary Figure 2-Stat.4 for panel
E). Differences between the means of three or more groups were determined by MANOVA. Differences between three or more samples were determined by
one-way ANOVA test. Pairwise comparison was performed with Student’s t-test (see Supplementary Figures -Stat). (D) mRNA levels of SNAI1, CDH2,
VIM and PAI genes in cells induced for 90 min with TGF-1 determined by qPCR. Total RNA was isolated, reverse transcribed and amplified by qPCR
with specific primers (Supplementary Table S1). The values were normalized to 18S RNA. RNA was isolated as described in the ‘Materials and Methods’
section. *P < 0.01 versus basal (without TGF-1); ◦P < 0.01 versus TGF-1 alone. The actual P-values are shown in Supplementary Figure 2-Stat.1. (E)
mRNA levels of WIF1, cMYC, CDH1 and DSP1 genes in cells induced for 90 min with TGF-1. The values were normalized to 18S RNA. *P < 0.01
versus basal (without TGF-1); ◦P < 0.01 versus TGF-1 alone. The actual P-values are shown in Supplementary Figure 2-Stat.3. (F) mRNA levels of
SNAI1, CDH2, VIM and PAI genes in cells induced for 90 min with TGF-1 by qPCR. MCF10A cells were pretreated with TCP (1 g/ml) for 60 min
and stimulated with 10 ng/ml TGF-1 for 90 min. The values were normalized to 18S RNA. *P < 0.01 versus basal (without TGF-1); ◦P < 0.01 versus
TGF-1 alone. The actual P-values are shown in Supplementary Figure 2-Stat.5. (G) mRNA levels of WIF1, cMYC, CDH1 and DSP1 genes in cells
induced for 3 h with TGF-1 and pretreated with TCP (1 g/ml) for 60 min. The values were normalized to 18S RNA. *P < 0.01 versus basal (without
TGF-1); ◦P < 0.01 versus TGF-1 alone. The actual P-values are shown in Supplementary Figure 2-Stat.7. Association between the mRNA levels after
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Figure 3. 2D UPLC–MS/MS analysis of DNA derived from cells stimulated with TGF-1 for various periods of time (left panels) or for 60 min in the
presence of DPI, apocynin, shCTRL or shLSD1 (right panels). The technical and statistical details are indicated in the ‘Materials and Methods’ section
and in Supplementary Figure 3-Stat.1–5. Results are the mean of at least three experiments in triplicate (n ≥ 9). Left panels: Multivariate analysis of
repeated measures (RM-MANOVA) was used to determine differences in multiple dependent variables over time. Pairwise comparison was performed
with Student’s t-test. *P < 0.01 versus time zero. The actual P-values are shown in Supplementary Figure 3-Stat.1–2. Right panels: The effect of TGF-1
in the various treatment conditions was evaluated with the Wilcoxon signed-rank test (Supplementary Figure 3-Stat.3). Differences between three or more
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Figure 4. TGF-1-induced phospho-SMAD2/3 interact with LSD1 and form a transient complex at the WIF1 and SNAI1 promoters. Chromatin from
MCF10A cells stimulated with 10 ng/ml TGF-1 for 30, 60 and 90 min was immunoprecipitated with antibodies to SMAD2/3 or phospho-SMAD2/3,
anti-LSD1. DNA was extracted and amplified with primers corresponding to SNAI1 (A) or WIF1 (B) promoters or as control the promoter region of human
TSH receptor gene, TSHR (C). Normal mouse or rabbit pre-immune IgG was used as a negative control (horizontal lines in each graph). The bar graph
shows the qPCR signals in immunoprecipitates, normalized to input DNA from each sample. Multivariate analysis of repeated measures (RM-MANOVA)
was used to determine differences in multiple dependent variables over time (Supplementary Figure 4-Stat.1A, C and E). Differences between three or more
samples were determined by one-way ANOVA test; pairwise comparison was performed with Student’s t-test (Supplementary Figure 4-Stat.1B, D and F).
*P < 0.01, in 90-, 60- or 30-min TGF-1-stimulated cells versus control. **P < 0.01, in 90-min compared to 60-min TGF-1-treated cells. The primers
used are shown in Supplementary Table S1. (D) Immunoprecipitation of LSD1 and immunoblot with anti-phospho-SMAD2/3, LSD1, SMAD2/3 and
LAMININ 1 antibodies in cells exposed for 30 min to TGF-1. (E) Immunoprecipitation of exogenous FLAG–LSD1 with anti-FLAG antibodies and
immunoblot with anti-phospho-SMAD2/3 and SMAD2/3. (F) Immunoprecipitation of SMAD2/3 and immunoblot with LSD1, SMAD2/3 and tubulin
antibodies in cells exposed for 30 min to TGF-1. ChIP of SNAI1 (G), WIF1 (H) and TSHR (I) gene promoters with antibodies versus phospho-SMAD2/3.
The DNA immunoprecipitated was subjected to re-ChIP with anti-LSD1 antibody. Data are reported as mean ± SD of three experiments in triplicate (n
= 9). Pairwise comparison was performed with Student’s t-test. *P < 0.01, TGF-1-stimulated cells versus control (Supplementary Figure 4-Stat.2). The
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Figure 5. Chromatin changes induced by TGF-1 at repressed and activated promoters. Chromatin from MCF10A cells stimulated with 10 ng/ml TGF-1
for 30, 60 and 90 min was immunoprecipitated with antibodies to OGG1 or APE1 (A–C), anti-H3K4me2/3 (D–F), anti-H3K9me2/3 (G–I) or anti-H3
(J–L). DNA was extracted and amplified with primers corresponding to SNAI1 (left panels) or WIF1 (middle panels) promoters or as control the promoter
region of human TSH receptor gene, TSHR (right panels). Normal mouse or rabbit pre-immune IgG was used as a negative control (horizontal lines in each
graph). The bar graph shows the qPCR signals in immunoprecipitates, normalized to input DNA from each sample. Data are reported as mean ± SD of
three experiments, performed, at least, in triplicate (n ≥ 9). Multivariate analysis of repeated measures (RM-MANOVA) was used to determine differences
in multiple dependent variables over time (Supplementary Figure 5-Stat.1–3A, D and G). Differences between three or more samples were determined
by one-way ANOVA test (Supplementary Figure 5-Stat.1–3). Pairwise comparison was performed with Student’s t-test. *P < 0.01, in 90-, 60- or 30-min
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ures S4D and E, and S4-Stat.2). In contrast, H3K9me2–3
and H3K4me2–3 levels at the same promoters varied con-
siderably between 30 and 90 min after TGF-1 treatment
(Figure 5D and E). Briefly, the most prominent H3K4 and
K9 methylation changes upon TGF-1 treatment are the
following: (i) A time-dependent increase of H3K4me3 at
SNAI1 promoter (Figure 5D and E) due to methylation
of H3K4me2 (Supplementary Figures S4D and S4-Stat.2).
(ii) A progressive reduction of H3K4me2 and H3K4me3 at
WIF1 promoter, due to H3K4me2 and H3K4me3 demethy-
lation, notwithstanding the rise at 90 min of the methyl-
transferase SET7/9 (Figure 5E, and Supplementary Fig-
ures S4E and S4-Stat.2). These changes are consistent with
the induction of SNAI1 and the inhibition of WIF1 expres-
sion by TGF-1 treatment. (iii) The monoamine oxidase in-
hibition activity by TCP increased H3K4me2 levels at the
WIF1 (Supplementary Figures S5B and S5-Stat.1–2) and
the levels of H3K9m2 at the SNAI1 promoters (Supple-
mentary Figures S5D and S5-Stat.3), notwithstanding the
recruitment of the methyltransferases SUV39 and SET7/9
(Supplementary Figure S4E). Although TCP inhibits non-
specifically monoxidases, it increases the global levels of
H3K4me2, which is the natural LSD1 substrate (Supple-
mentary Figure S5J). The methylation changes induced by
TCP are consistent with the inhibition of TGF-1 induc-
tion or repression of SNAI1 and WIF1 transcription as in
cells in which LSD1 has been depleted (Figure 2D–G). The
methylation changes induced by TCP were associated with a
significant depletion of nucleosomes at the WIF1 promoter,
as shown by loss of H3 at 30 and 90 min (Supplementary
Figures S5H and S5-Stat.4).
Collectively, the levels of H3K9m2 and H3K4m2, the
timing of LSD1 recruitment and the effects of TCP on the
H3K4m2 and H3K9m2 levels suggest that LSD1 recruit-
ment and activity mediate the induction of SNAI1 and the
repression of WIF1 by TGF-1 (Figure 4A and B).
Also, the H3K9me2 reduction of H3K9me2 levels at the
chromatin of the SNAI1 promoter in the first 30 min with-
out a concomitant increase of H3K9me3 (Figure 5G) sug-
gests that H3K9me2 is the main LSD1 substrate at the
SNAI1 promoter, as previously shown at the chromatin
of genes induced by nuclear receptors (12,13). Finally, the
steady H3K4me3 increase and the concomitant reduction
in H3K4me2 after 60 min of TGF-1 stimulation at the
SNAI1 promoter can be explained by the recruitment of
the methyltransferase SET7/9 following 30 min of TGF-1
stimulation (Figure 5D and Supplementary Figure S4D).
The H3K9me2 chromatin modification induced by LSD1
(Figure 5G) was consistent with the loss of TGF-1 induc-
tion and repression of target genes upon LSD1 depletion or
TCP exposure (Figure 2D–G).
Cooperation between two histone demethylases, LSD1 and
JMJD2A, mediated TGF-1-induced EMT
LSD1 demethylates H3K4me2 and H3K9me2 but not
trimethyl K4 or K9 (47). To account for the H3K9me3
changes at the SNAI1 and WIF1 promoters, we deter-
mined the effects of TGF-1 on a different type of histone
demethylase, KDM4A (also called JMJD2A or JHDM3A),
a dioxygenase that demethylates H3K9me3 and H3K9me2
in an oxidation reaction that requires Fe2+ (48). Notably,
KDM4A/JMJD2A is exquisitely sensitive to oxygen levels
and displays a graded response to oxygen depletion (49).
JMJD2A depletion inhibited the nuclear 8-oxo-dG signal
and TGF-1-induced EMT (Supplementary Figure S6A–
D). JMJD2A, upon TGF-1 stimulation, was recruited to
the SNAI1 promoter and marginally to the WIF1 promoter
30 min after treatment (Supplementary Figure S6I and
J). JMJD2A depletion reduced the expression of SNAI1,
CDH2, VIM and PAI induced by TGF-1 (Supplementary
Figure S6E and F), but did not change TGF-1-mediated
repression of WIF1, MYC, CDH1 and DSP (Supplemen-
tary Figures S6G and H, and S6-Stat.1–7). The same phe-
notype was observed by inhibiting JMJD2 activity with
JIB04 (50,51) (Supplementary Figures S3 and S6-Stat.1–7).
We conclude that JMJD2A cooperates with LSD1 to acti-
vate TGF-1-induced EMT genes and it is not required for
TGF-1 silencing of epithelial genes.
Repression of transcription by TGF-1 is dependent on both
nuclear and cytoplasmic ROS
Collectively, the above data demonstrated that LSD1 is in-
volved in both TGF-1 induction and repression of tran-
scription depending on the histone methylation code and
partnership with other factors, such as pSMAD2/3 or
SNAI1 recruited at activated or repressed promoters, re-
spectively. ROS are central to both activation and repres-
sion of transcription by TGF-1 (Figure 1F and G), and
their source might be relevant for the efficiency of the final
transcriptional response.
Early (30–90 min) TGF-1-mediated transcription in-
duction or repression can be explained by the activation of
two major signaling pathways, both of which require LSD1.
The first, which leads to transcription activation, includes
nuclear ROS, pSMAD2/3, LSD1 and JMJD2A/KDM4A.
The second, which represses transcription, is established
by the LSD1–SNAI1 complex, and, eventually, maintained
by the co-repressors NCoR1–HDAC3 (Figures 1F and G,
and 2A, F and G).
To get insight into the other signaling element(s) that co-
operate with LSD1 to mediate TGF-1 transcription re-
pression, we exposed TGF-1-treated cells to several chem-
ical inhibitors to identify the primary source of the ROS:
(i) rotenone (52), an inhibitor of mitochondrial complex I,
which has been linked to TGF-1-induced ROS; (ii) apoc-
ynin, which is a generic antioxidant, which does not mod-
ify nuclear oxo-dG accumulation by TGF-, but inhibits
peroxides (36,53); and (iii) SP600125, a specific inhibitor of
JNK (54), the ROS-activated kinase that mediates WIF1 si-
lencing by ROS and ATM (41,55).
Although the ROS inhibitors we have used were not as
specific as the silencing probes, we can extract the follow-
ing information: (i) Apocynin prevented repression of tran-
scription by TGF-1 (Supplementary Figure S7D) but did
not reduce oxo-dG detected by MS (Figure 3A). (ii) DPI
prevented repression of transcription by TGF-1 (Figure
1G) and reduced nuclear oxo-dG detected by MS (Figure
3A). (iii) Both drugs did not influence the induction of tran-
scription by TGF- 1 at early times, while an ROS scavenger
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scription by TGF-1 (Figure 1F and Supplementary Figure
S6C). At 24 h, DPI inhibited NOX4 and SNAI induction
by TGF-1 (Supplementary Figure S1A and B) (26,28,29).
(iv) SP600125, the JNK inhibitor, did not influence TGF-
1-induced gene expression (Supplementary Figure S7A),
but prevented TGF-1 silencing of WIF1, MYC, CDH1
and DSP genes (Supplementary Figures S7B and S7-Stat.1–
5), data that replicate the effects of DPI (Figure 1F-G).
(v) Unexpectedly, inhibition of mitochondrial complex I by
rotenone did not affect early TGF-1 repression of EMT
genes, data that suggest mitochondrial ROS do not medi-
ate TGF-1 early inhibition of transcription, notwithstand-
ing the presence of SNAI1 repressor (Supplementary Figure
S7C and D). These results imply that at 2 and 24 h there are
two pharmacologically different sources of ROS induced by
TGF-1. At 24 h, the major player is NOX4 and this has
been demonstrated in many laboratories and we now know
that NOX4 is induced at 24 h, and its expression is inhibited
by DPI (Supplementary Figure S1A) (25,26). At early times,
LSD1 is the main source of nuclear ROS and is essential
for both induction and repression of transcription by TGF-
1. However, the data shown in Supplementary Figure S7
suggest that another early source of ROS (JNK) is neces-
sary for the early inhibition of transcription by TGF-1.
Here, we provide an experimental tool to separate the in-
duction and repression of transcription by TGF-1 at early
(hours) and late (days) times. Notably, SNAI1, which is con-
sidered essential for TGF-1/LSD1 repression of epithelial
genes (31) in the presence of DPI, did not repress early tran-
scription (Figure 1F and G, and Supplementary Figure S7C
and D). We believe that this information is relevant because
SNAI1 is considered the master repressor of transcription
induced by TGF-1 (31).
DISCUSSION
The role of ROS in the regulation of EMT in several cell
types, including tumor models, is the subject of active in-
vestigation (5,6). Oxidative stress following the exposure
of cells to microenvironmental insults, such as hypoxia or
contact with stromal or inflammatory cells (i.e. CAFs or
macrophages), has been causally associated with EMT ac-
tivation. In redox-dependent EMT, there are at least two
molecular axes driven by pro-inflammatory/pro-oxidant
sensors: one involves HIF-1 and NF-B and the other in-
volves the Rac-1 small GTPase, NOX and Src kinase (5,6,8).
With our data, we identified another element that plays
a relevant role in the EMT transcriptional program: ROS
induced by TGF-1 in the nuclear compartment by the
histone demethylase LSD1 (Figure 2B) were essential for
the induction, repression of transcription and the initia-
tion of the TGF-1-mediated EMT program (Figures 1
and 2). LSD1 was targeted to promoter sites activated or
repressed by TGF-1 by phospho-SMAD2/3 (Figure 4A
and B).
Phosphorylated SMAD2/3 and LSD1 targeted TGF-1-
induced and -repressed genes
Induction of phospho-SMAD2/3 by TGF-1 is a central
event (29,37) that initiates the EMT transcriptional pro-
gram. Although SMAD2 does not directly bind to DNA,
the SMAD2/3 complex recognizes specific, essential se-
quence motifs present at the transcription start site (TSS)
and enhancers of many TGF-1-induced or -repressed
genes (29,37,38). These SMAD2/3 signatures were also
present in the TGF-1-induced or -repressed genes ana-
lyzed here. Phosphorylated SMAD2/3 work as a pioneer
factors that mark several genomic sites of TGF-1-induced
or -repressed promoters in different cell types (38–40). De-
pending on the cell context and the presence of other fac-
tors, some genes will be induced and others will be inhibited.
Our data suggest that the cellular context is represented by
different ROS sources.
TGF-1 genomic oxidative signature initiated the EMT pro-
gram
TGF- induces nuclear migration of SMAD proteins,
which are phosphorylated by several kinases, including
stress kinases, JNK and p38 (41). PhosphoSMAD2/3 com-
plex binds and targets LSD1 to the promoters of genes such
as SNAI1 and WIF1, which are induced or repressed, re-
spectively, by TGF-1 (Figure 4A and B). LSD1 induced
a peak of 8-oxo-dG, detectable by recruitment of OGG1
and APE1 at SNAI1 and WIF1 promoters (Figure 5A and
B). Local dG oxidation at these two promoters reflected a
massive oxidation wave across the entire genome induced by
TGF-1, detectable by MS and dependent on LSD1 (Fig-
ure 3). G and C are oxidized in vivo by two mechanisms. In
the first, G is oxidized by a Fenton reaction catalyzed by
LSD1, which generates hydrogen peroxide (33), and partly
by KDM4A/JMJD2A (dependent on Fe2+) (48). In the sec-
ond, C is oxidized by ten–eleven translocation (TET) en-
zymes that use ketoglutarate as a cofactor and Fe2+ as
an electron donor (similar to all JMJ enzymes). Hydrox-
ymethylation of 5mhC is the obligatory step to C demethy-
lation and transcription activation (56). Although G oxi-
dation was the major genomic change induced by TGF-,
we notice that the global levels of 5OHmdC were higher
in cells exposed for 60 and 90 min to TGF- (Figure 3B).
Collectively, G and C oxidation marks the global transcrip-
tion changes induced by TGF- during the initiation of the
EMT (Figure 3).
DNA oxidation and transcription
Targeted oxidation of DNA at enhancers, TSSs and 3′ ends
of genes is essential for the formation of chromatin tran-
scription loops and the initiation complex (12,13,57). In
fact, transcription loops induced by retinoic acid or es-
trogens do not form when LSD1 or OGG1 is downregu-
lated or oxidation (12,13) and/or repair (12,58) are pre-
vented. The 8-oxo-dG peak induced by 30–90-min TGF-
1 treatment corresponds to the time required to stabilize
chromatin loops during initiation of transcription by estro-
gens or retinoic acid. These loops are RNase H sensitive,
recruit LSD1, OGG1 and cohesin RAD21, and connect
the enhancer–TSS and polyA sites (12,13,57). The oxidized
sites form single-strand nicks that recruit topoisomerase II
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and NER (12,13). These events occur in a precise temporal
window (12,13,57), and histone demethylation and G oxi-
dation are the first critical steps (12,13). We note that the
punctuated oxo-dG signal detected by confocal microscopy
(Figure 2A and B) resembles the interchromatin granules
or nuclear speckles containing RNA splicing and transcrip-
tion factors. Proteomic analysis shows that SMAD4, OGG1
and APE1 are stable components of these nuclear structures
that associate transcription factories with the early RNA
processing complex (59).
OGG1 was recruited to the promoter of repressed genes,
including WIF1, at 30 and 90 min after TGF-1 treatment.
At 30 min, OGG1 was present at both the SNAI1 and WIF1
promoters, while at 90 min after TGF-1 treatment OGG1
accumulated only at WIF1 promoter (Figure 5A and B),
suggesting that the second dG oxidation event, also visible
by MS, was required for WIF1 silencing. This late oxida-
tion corresponded to the bulk of TGF--induced oxidation
and was dependent on LSD1 (Figure 3A). Transcriptional
repression by TGF-1 was established at the WIF1 pro-
moter following the dissociation of the pSMAD2/3–LSD1
complex (Figure 4A). The TGF-1 inhibitor, SB431542,
prevented SMAD2/3 phosphorylation (60) and LSD1 re-
cruitment at SNAI1 and WIF1 promoters (A. Pezone, un-
published data) suggesting that LSD1 targeting at TGF-
1-responsive promoters was dependent on pSMAD2/3.
We suggest that LSD1 is stabilized at the WIF1 promoter
by HDAC3–NCoR1 and SNAI1 (Supplementary Figures
S4B and S5B) only if there is a steady ROS signal that acti-
vates JNK. In this context, it is worth noting the following:
(i) ROS activate JNK and stabilize HDAC3 bound to the
WIF1 promoter to silence the gene (38) and (ii) metabolism
and ROS control JNK levels and activity (55,61). The for-
mation of the repressor complex at the WIF1 promoter
is not trivial because it represents an important arm of
the TGF-1 signaling pathway. WIF1 is the main secreted
WNT1 inhibitor and its silencing substantially amplifies
WNT1 signaling and fibrosis in vivo (55).
Repression of EMT genes requires synchronous signaling
from JNK and LSD1
LSD1 is neutral with regard to activation or repression, but
it is a coincidence sensor at the WIF1 promoter because its
presence reflects a steady ROS signal leading to JNK ac-
tivation and a nuclear oxidation signal, both necessary to
repress transcription. In the absence of the ROS–JNK sig-
nal, LSD1 binds pSMAD2/3, activates SNAI transcription
and marks transiently WIF1 promoter 30 min after TGF-1
treatment. In the presence of a persistent ROS signal (90-
min TGF-1 treatment), LSD1 binds to SNAI1–NCoR1–
HDAC3 and induces a new demethylation-oxidative wave
by removing activation marks from chromatin (Figure 5E).
In fact, while LSD1 depletion inhibited both genes that
are positively and negatively regulated by TGF-1, tran-
scription repression was achieved only in the presence of a
concomitant and strong DPI/JNK–ROS signal. The early
repressor induced by TGF-1, SNAI1, does not repress
transcription in the absence of this signal (Figure 1G and
Supplementary Figure S7D). Instead, nuclear oxidation by
LSD1 in the absence of JNK–ROS was sufficient to activate
Figure 6. LSD1–phospho-SMAD2/3 complex targets genes induced or re-
pressed by TGF-1. Schematic cartoon summarizing the action of TGF-
1 to induce or repress transcription of EMT genes. Upon SMAD2/3
phosphorylation, induced by TGF-1, LSD1 binds pSMAD2/3 and tar-
gets TGF-1-inducible or -repressed genes, containing SMAD signatures
(GAATCC) (37,38). Following the local DNA oxidation elicited by LSD1
and JMJD2A, 5′–3′ transcription loops and the transcription initiation
complex are assembled and transcription begins (12,13,58). At the re-
pressed genes, instead, if NOX–ROS are persistent and JNK is active, a
repressor complex, containing HDAC3, NCoR1, SNAI1 and LSD1, shuts
off transcription (41). At these sites, LSD1 demethylates H3k4me2 and
stabilizes repression of transcription (33).
TGF-1/EMT genes, including SNAI1 (Figure 2F and G,
and Supplementary Figure S7A and C).
Initiation, establishment and maintenance of TGF-1-
induced EMT
We wish to stress that our observation window of TGF-
1 effects is narrow (0–90 min) compared to the timing of
TGF-1 action analyzed in the majority of published stud-
ies, which show that NOXs, and specifically NOX4, are es-
sential for stable EMT (24–48 h to 15 days) (28,29). Our
results complement and do not contradict the published
data because the changes we document are transient and
reversible. This is shown by the activation of the canonical
TGF-/SMAD pathway, which initiates a transient wave
of SMAD2/3 phosphorylation (Figure 4) (60,62). In fact,
if TGF-1 is removed after 3 h to 9 days, the EMT pheno-
type and the induced proteins disappear. Higher doses and
continuous exposure to TGF-1 stabilize irreversibly the
EMT phenotype (63); see also the comments in (64). Our
data show that the early events following TGF-1 exposure
are relevant for the initiation of the EMT program and sug-
gest that the early (1–2 h) and late (24 h) events triggered by
TGF-1 to induce EMT are mediated by a combination of
different players.
We propose that the TGF-1 EMT transcriptional pro-
gram is carried out in two distinct temporal phases: the
first (initiation), between 30 and 90 min, initiates the pro-
gram by modifying DNA at multiple sites. On a smaller
scale, the complex pSMAD2/3–LSD1 primes genomic sites
that eventually will be stably activated or repressed only if
the TGF-1 signal is continuous and persistent (Figure 5)
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days, consolidates and stabilizes TGF-1 transcriptional re-
pression or induction (28,29). Although we did not identify
precisely the source of the DPI-sensitive ROS in the initi-
ation phase (90-min TGF-1 treatment), we suggest that
JNK–NCoR1 and HDAC3 are essential for the stabiliza-
tion and maintenance of early TGF-1 repression of tran-
scription (55).
Figure 6 shows a simplified scheme of the early TGF-
1 signals. It describes the induction or repression of tran-
scription of EMT genes. Specifically, the repressor complex
enucleated by LSD1 at the WIF1 promoter inhibits tran-
scription only when two temporally close and spatially dis-
tributed signals are present, i.e. nuclear (LSD1) and cyto-
plasmic (NOX–JNK) ROS. This repressor complex is an
ROS sensor and is linked to the redox state of the cell (55).
We speculate that the source of cytoplasmic ROS is linked
to the metabolism, may vary from cell to cell and represents
the so-called cell context, which substantially modifies the
response to TGF-1 in a cell-specific fashion.
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Avvedimento,E.V. and Santillo,M. (2016) Reactive oxygen species
derived from NOX3 and NOX5 drive differentiation of human
oligodendrocytes. Front. Cell. Neurosci., 10, 146.
19. Gackowski,D., Starczak,M., Zarakowska,E., Modrzejewska,M.,
Szpila,A., Banaszkiewicz,Z. and Olinski,R. (2016) Accurate, direct,
and high-throughput analyses of a broad spectrum of endogenously
generated DNA base modifications with isotope-dilution
two-dimensional ultraperformance liquid chromatography with
tandem mass spectrometry: possible clinical implication. Anal.
Chem., 88, 12128–12136.
20. Chiarugi,P., Pani,G., Giannoni,E., Taddei,L., Colavitti,R.,
Raugei,G., Symons,M., Borrello,S., Galeotti,T. and Ramponi,G.
(2003) Reactive oxygen species as essential mediators of cell adhesion:
the oxidative inhibition of a FAK tyrosine phosphatase is required for
cell adhesion. J. Cell Biol., 161, 933–944.
21. Cichon,M.A. and Radisky,D.C. (2014) ROS-induced
epithelial–mesenchymal transition in mammary epithelial cells is
mediated by NF-B-dependent activation of Snail. Oncotarget, 5,
2827–2838.
22. Lou,Z., Wang,A.-P., Duan,X.-M., Hu,G.-H., Song,G.-L., Zuo,M.-L.
and Yang,Z.-B. (2018) Upregulation of NOX2 and NOX4 mediated
by TGF- signaling pathway exacerbates cerebral
ischemia/reperfusion oxidative stress injury. Cell. Physiol. Biochem.,
46, 2103–2113.
23. Liu,R.-M. and Desai,L.P. (2015) Reciprocal regulation of TGF- and
reactive oxygen species: a perverse cycle for fibrosis. Redox Biol., 6,
565–577.
24. Michaeloudes,C., Sukkar,M.B., Khorasani,N.M., Bhavsar,P.K. and
Chung,K.F. (2011) TGF- regulates Nox4, MnSOD and catalase
expression, and IL-6 release in airway smooth muscle cells. Am. J.
Physiol. Lung Cell. Mol. Physiol., 300, L295–L304.
25. Boudreau,H.E., Casterline,B.W., Rada,B., Korzeniowska,A. and




















IA user on 28 July 2020
16 Nucleic Acids Research, 2020
induction of the epithelial-to-mesenchymal transition and migration
of breast epithelial cells. Free Radic. Biol. Med., 53, 1489–1499.
26. Hiraga,R., Kato,M., Miyagawa,S. and Kamata,T. (2013)
Nox4-derived ROS signaling contributes to TGF--induced
epithelial–mesenchymal transition in pancreatic cancer cells.
Anticancer Res., 33, 4431–4438.
27. Shanmugasundaram,K., Nayak,B.K., Friedrichs,W.E., Kaushik,D.,
Rodriguez,R. and Block,K. (2017) NOX4 functions as a
mitochondrial energetic sensor coupling cancer metabolic
reprogramming to drug resistance. Nat. Commun., 8, 997.
28. Augsburger,F., Filippova,A., Rasti,D., Seredenina,T., Lam,M.,
Maghzal,G., Mahiout,Z., Jansen-Dürr,P., Knaus,U.G., Doroshow,J.
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